Trial Profile
Phase II study of cetuximab in combination with cisplatin-docetaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a biomarker-based assessment of activity.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2011
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 02 Jul 2011 New trial record